ThermoGenesis Holdings, Inc. · OTC:THMO

ThermoGenesis — Cesca Therapeutics — Biotech Showcase 2018

21 slides from ThermoGenesis's conference presentation, Jan 16, 2018

  1. Slide 1: Chris Xu, Ph.D. Chairman and CEO, Biotech Showcase

    Exhibit 99.1 Chris Xu, Ph.D. Chairman and CEO Biotech Showcase January 9, 2018

  2. Slide 2: Forward looking statement

    Forward looking statement This presentation includes statements of future expectations and other forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current views and assumpt

  3. Slide 3: Quick financial snapshot

    Bae ee Ne 50 ie 38 oe oe oe oe eee ieee Quick financial snapshot Share Price* $3.21 52-Week Range $2.62 - $6.44 Shares Outstanding** 10.9M Market Capitalization $35.0M Revenue (TTM)*** $14M Cash*** $2.5M Largest Shareholder Boyalife Group (63%) Warrants Outstanding**** 4.1M * January 5, 2018 a 1 off

  4. Slide 4: CAR-T is a major advancement in I/O cell therapy

    Bae ee Ne 50 ie 38 oe oe oe oe eee ieee Car-Tis a major advancement in I/O cell therapy + 70+ U.S.-registered trials underway * 70-92% Complete Response rates for relapsed/refractory Acute Lymphoblastic Leukemia (ALL); impressive early clinical results in other hematologic cancers + Breakthrough the

  5. Slide 5: First CAR-T therapy approved

    irst CAR-T therapy approved ( /per patient) Science, 2006 October 6: 314(5796): 126-129. Emily's Story: A Young Girl Beats Cancer with Immunotherapy Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes Richard A. Morgan, Mark E. Dudley, John R. Wunderlich, Marybeth S. H

  6. Slide 6: Why is CAR-T so expensive? Manual manufacturing processes

    hy is CAR-T so expensive? — the manual manufacturing processes Labor-intensive manual steps, highly variable, open systems, low yield, low efficiency > high cost The Short Version: Isolate (Collect) 6 | NASDAQ: KOOL

  7. Slide 7: Why does CAR-T cell process efficiency matter?

    Ee S95 50 N50 5 9 oe 8 os a a a hee ieee Why does CAR-T cell process efficiency matter? ~ 7 “Because refractory B cell malignancies can progress quickly, it is important to reduce the time between apheresis of patient PBMCs and Time to patient is a matter of administration of the engineered T cells.

  8. Slide 8: Our product portfolio

    Our product portfolio — In July, 2017, Cesca acquired SynGer' to develop automation for CAR-T therapies || BioBanking | Point-of-Care Cesca Product SynGen Product 1 On July 10, 2017, Cesca Therapeutics announced that its wholly-owned subsidiary, ThermoGenesis Corp., acquired the cell processing syst

  9. Slide 9: Development of CAR-TXpress platform

    Development of CAR-TXpress™ platform —— Automated system for large scale manufacturing of CAR-T cells with high efficiency :* joleBlood BMA. Leukapheresis Unit IL-2, CD3, Volumes May Exceed 5 L DNA Gene Insertion Additional IL-2 Infused Selection of CI Volume aa ea a [ Se Dama Redcoanest 4 10-14 day

  10. Slide 10: Core technology — X-LAB for high efficiency cell isolation

    Core technology — X-LAB™ for high efficiency cell isolation —WNon-ficoll based isolation of MNCs from various sources (blood, leukopheresis) Advantage: No ficoll use ASmLMedium] predepositedin T harvest chamber ‘axis ofrotation of awing bucket centrfugeis parllelto the floor 2000%9, 20 min 50x93 min

  11. Slide 11: Core technology — buoyance activated cell sorting (BACS)

    Core technology — buoyance activated cell sorting (BACS) What It Is: + BACS uses microscopic bubbles (each smaller than a single cell) as cell isolation reagents. * The microbubbles are ruggedized with lipid shells, to which antibodies are attached to bind them only to the target cell type in a mixt

  12. Slide 12: Core technology — X-WASH for washing & reformulation

    Core technology — X-WASH™ for washing & reformulation — High efficiency washing and re-formulation technology Cell suspension added to buffer in central chamber; buffer added to harvest chamber Car ige snapped on to Control Module, placed in centrifuge (3] Retrieve Washed Cells ‘Washed cells re-susp

  13. Slide 13: Processing report for CGMP/CMC compliance

    Processing report for CGMP/CMC compliance —— CAR-TXpress™ is designed to be in compliance with CMC manufacturing requirement SynGenx Processing Report Unie 1D: cm54 F-Reg (Ca a ie cma Time (Seconds) Depletion Valve Open Duration (sec): Harvest Valve open Duration (sec): Harvest Target Volume (mt): C

  14. Slide 14: CAR-TXpress platform — a major leap in CMC manufacturing

    Car-txpress platform — a major leap in CMC manufacturing —— Semi-automated system for large scale manufacturing of CAR-T cells with high efficiency X-LAB MNC Isolation | wo Ld “— [oF pees ABoyale Company Hours ° 2 3 4 14 | NASDAQ: KOOL

  15. Slide 15: CAR-TXpress platform — a major leap in CMC manufacturing

    Car-txpress platform — a major leap in CMC manufacturing —— Semi-automated system for large scale manufacturing of CAR-T cells with high efficiency oa 94.3 70 65.0 50 m= MNC Isolation MLMINC & CD3+ Selection % Recovery 30 20 10 o+ X-LAB &X-BACS* Ficoll & Magnetic Beads*# * Internal Data ** Red blood

  16. Slide 16: Intellectual property — CAR-TXpress Platform

    Intellectual property-— CAR-TXpress™ Platform I. Protects X-LAB, X-WASH, X-BACS “System for purifying certain cell populations by depleting others” Apparatus Claims Issued: USA, Australia, Canada, China, Japan, Malaysia, Mexico, Russia, Singapore (2012-2017) Pending: Europe, India, South Korea Metho

  17. Slide 17: Growth strategy

    Growth strategy Our goal is to become the leading provider of closed-system automation for cell-based therapeutics by capturing the rapidly growing immuno-oncology market. A Cc =) Stem Cell & CAR-T & Regenerative Medicine Immuno-Oncology Device Clinical CAR-TXpress™ “~~ Ss os BioBanking Point-of-Car

  18. Slide 18: What we accomplished in 2017

    BO 502050 5050 28 28 22 28 oe 2 oe oe ee ee ees What we accomplished in 2017 Implementation of new strategic vision and corporate goals Strengthened board of directors New executive team with proven track record: CEO & COO Closed strategic acquisition of SynGen Inc. Secured international distributio

  19. Slide 19: Investment highlights

    Bae ee Ne 50 ie 38 oe oe oe oe eee ieee Investment highlights > Well-positioned to be a leading player in automated CAR-T and CAR-NK cell CMC manufacturing > Able to leverage the strong growth of the immuno-oncology market > Strong IP position > CAR-TXpress™ to be a platform technology for diverse a

  20. Slide 20: Experienced leadership team

    Experienced leadership team OBc EDR 20 | NASDAQ: KOOL Chris Xu, PhD/MBA, Chairman, President and Chief Executive Officer Boyalife Group (founder), Pfizer, Founder Group Joined Cesca in March 2016 as Director, becoming CEO in Nov 2016 Vivian Liu, Chief Operating Officer and Director OxOnc Services Co

  21. Slide 21: Investor Contact

    Investor Contact: Paula Schwartz RX Communications pschwartz@rxir.com 917-322-2216 Thank You!

Cesca Therapeutics — Biotech Showcase 2018 on 6ix